Volver a bibliografía

Problemas del sistema nervioso

Hale N, Paauw D. Diagnosis and Treatment of Headache in the Ambulatory Care SettingA Review of Classic Presentations and New Considerations in Diagnosis and Management. Med Clin N Am 98. 2014:505-27.
Hao Q, Tampi M, O'Donnell M, Foroutan F, Siemieniuk RA, Guyatt G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. BMJ. 2018 Dec 18;363:k5108. doi: 10.1136/bmj.k5108.
May Y. Hints on Diagnosing and Treating Headache Dtsch Arztebl Int. 2018 Apr; 115(17): 299–308. Published online 2018 Apr 27. doi: 10.3238/arztebl.2018.0299
Murdin L, Hussain K, Schilder A. Betahistina para los síntomas del vértigo. Cochrane Database of Systematic Reviews 2016 Issue 6. Art. No.: CD010696.
Pharmacological management of migraine. Edinburgh: SIGN; 2018.(SIGN publication no. 155). [February 2018]. Available from: http://www.sign.ac.uk
Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020 Feb 13;368:l6983. doi: 10.1136/bmj.l6983.
Sánchez Álvarez JC, Ruiz Giménez J, Roldán Aparicio S, Serrano Castro P. Sociedad Andaluza de Epilepsia. Guía Andaluza de Epilepsia 2015. Barcelona: Viguera Editores; 2015. Disponible en: https://escueladepacientes.es/images/Pdfs/SADE%20-%20Gu%C3%ADa%20Andaluza%20de%20Epilepsia%202015.pdf
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. NICE guideline. Published: 1 May 2019. (acceso 26-3-2020). Disponible en: www.nice.org.uk/guidance/ng128

Accidente cerebrovascular

CADIME. Doble antiagregación plaquetaria: indicaciones y duración. BTA CADIME. 2016;31(3). Disponible en: http://www.cadime.es/docs/bta/CADIME_BTA_31_3.pdf
Cucchiara BL, Messé SR. Antiplatelet therapy for secondary prevention of stroke Up ToDATE Aug 2018.
Gladstone WT. Canadian stroke best practice recommendations. Sixth Edition Update 2017 (FINAL). Disponible en: http://www.strokebestpractices.ca/prevention-of-stroke/
Guideline Development Group of the Intercollegiate Stroke Working Party. National clinical guideline for stroke. Fifth Edition 2016. Royal College of Physician. Disponible en: https://www.strokeaudit.org/SupportFiles/Documents/Guidelines/2016-National-Clinical-Guideline-for-Stroke-5t-(1).aspx
Lee M, Saver JL, Hong K-S, Rao NM, Wu Y-L, Ovbiagele B. Antiplatelet regimen for patients with breakthrough strokes while on aspirin. A systematic review and meta-analysis. Stroke. 2017; 48:2610-13.
Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020 Feb 13;368:l6983. doi: 10.1136/bmj.l6983.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49:e46-e99. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/STR.0000000000000158
Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events (Review) Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No.: CD005158.
Yang Y, Zhou M, Zhong X, Wang Y, Zhong Xi, Liu L, et al. Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis. Stroke and Vascular Neurology. 2018;3:e000168. doi:10.1136/svn-2018-000168

Arteritis de la temporal

Jivraj I, Tamhankar M. The Treatment of Giant cell arteritis. Curr Treat Options Neurol (2017) 19: 2.
Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006 Oct;54(10):3310-8.
Schmidt J, Warrington KJ. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging. 2011;28(8):651-66
Trobe J, Matteson EL. Treatment of giant cell arteritis. UpToDATE. Aug 2018.

Cefalea por abuso de medicamentos. Cefalea crónica diaria

Breaking the cycle of medication overuse headache. Ccjm. 2010 ;77,4:236-42.
Garza I, Schwedt TJ, Medication overuse headache: Treatment and prognosis. Up To DATE Aug 2018
Garza I, Schwedt TJ. Medication overuse headache: Treatment and prognosis. UpToDate. Mar 10. 2015.
Lovell B, Marmura MJ. New therapeutic developments in chronic migraine. Curr Opin Neurol. 2010;23:254-8.
Rizzato B, Leone G, Misaggi G, Zivi LL, Diomedi M. Efficacy and Tolerability of Pregabalin Versus Topiramate in the prophylaxis of Chronic Daily Headache With Analgesic Overuse: An Open-Label Prospective Study. Clinical Neuropharmacology. 2011;34,2:74-8.

Cefalea migrañosa. Migraña

Bajwa Z, MD, Smith JH, Acute treatment of migraine in adults. UpToDATE 2018.
Couch JR. Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache. Headache. 2011;51:33-51.
Harmon TP. Diagnosis and Management of Migraines and Migraine Variants. Prim Care Clin Office Pract. 2015;42:233-41.
Headaches. Diagnosis and management of headaches in young people and adults. Clinical Guideline. NICE 2012. Disponible en: guidance.nice.org.uk/CG/Wave23/2
Healthcare Improvement Scotland. Sign 155. Pharmacological management of migraine 2018. A national clinical guideline. SIGN; febrary 2018. Disponbile en: https://www.sign.ac.uk/assets/sign155.pdf
Mayan L, Walling A. Acute Migraine Headache: Treatment Strategies. American Family Physician, 2018-02-15, Volumen 97, Número 4, Páginas 243-251.
Ozkurt B, Cinar O, Cevik E, Acar AY, Arslan D, Eyi EY, et al. Efficacy of high-flow oxygen therapy in all types of headache: a prospective, randomized, placebo-controlled trial. Am J Emerg Med. 2012;2.
Shamliyan TA, Kane RL, Taylor FR. Migraine in Adults: Preventive Pharmacologic Treatments. Comparative Effectiveness Review No. 103. 2013. Disponible en: www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Cefalea en racimos

Ashkenazi A, Schwedt T. Cluster Headache-Acute and Prophylactic Therapy. Headache. 2011;51:272-86.
Cluster headache. BMJ Evidence 2008. Disponible en: http://clinicalevidence.bmj.com/ceweb/conditions/nud/1212/1212.jsp#Q1
Evers S. Pharmacotherapy of cluster headache. Expert Opinion on Pharmacotherapy. 2010;11(13):2121-7.
Kingston WS, Dodick DW. Treatment of Cluster Headache. Ann Indian Acad Neurol. 2018; 21(Suppl 1): S9–S15.
Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database of Systematic Reviews 2010.
Leone M, Giustiniani A, Cechini A P:. Cluster Headache. Present and future.. therapy Neurol Sci (2017) 38 (Suppl 1):S45–S50.
May A. Cluster hedache.Treatment and prognosis. Up To DATE Aug 2018.
Treatment of primary headache: cluster headache. Standards of care for headache diagnosis and treatment. Disponible en: http://www.guideline.gov/summary/summary.aspx?doc_id=6582&nbr=004142&string=cluster

Cefalea tensional

Derry, Sheena, Wiffen, Philip J, Moore, R Andrew. Aspirin for acute treatment of episodic tension-type headache in adults. (Protocol) Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD011888. DOI: 10.1002/14651858.CD011888.pub2.
Derry, Sheena, Wiffen, Philip J, Moore, R Andrew, Bendtsen, Lars. Ibuprofen for acute treatment of episodic tension-type headache in adults. (Protocol) Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD011474. DOI: 10.1002/14651858.CD011474.pub2
Espí-López GV, Gómez-Conesa A. Eficacia del tratamiento en la cefalea tensional. Fisioterapia. 2010;32(1):33-40.
Loder E, Rizzoli P. Tension-type headache. BMJ. 2008;336:88-92.
Soderberg E, Carlsson JY, Stener-Victorin E, Dahlo C. Subjective Well-being in Patients With Chronic Tension-type Headache: Effect of Acupuncture, Physical Training, and Relaxation Training. Clin J Pain. 2011;27:448-56.
Stephens, Guy, Derry, Sheena, Moore, R Andrew..Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. (Protocol) Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD011889. DOI: 10.1002/14651858.CD011889.pub2.

Demencia

Antipsicoticos: mala ciencia, pseudoinnovacion, prescripción desbordada y iatrogenia. Disponible en: http://www.icf.uab.es/es/pdf/informacio/bg/bg293-4.16e.pdf
Behavioral disturbance in patients with dementia; [updated 2016 Nov 22). DynaMed Plus [Internet]. Disponible en: http://www.dynamed.com/login.aspx.
Castellanos Pinedo F, Cid Gala M, Duque San Juan Zurdo M. Abordaje integral de la demencia. Inf Ter Sist Nac Salud. 2011;35:39-45.
Deprescripcion en demencia. Boletín de Información Farmacoterapéutica, 2020 (28): nº 2, Navarra.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE. 2011. Disponible en: http://www.nice.org.uk/TA111
Enfermedad de Alzheimer. Infac. 2010. Disponible en: http://www.osakidetza.euskadi.net/r85-pkfarm02/es/contenidos/informacion/cevime_infac/es_cevime/2010.html.
Farlow M, Shamliyan TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia . European Neuropsychopharmacology. 2017; 27: 217–31.
Guía de práctica clínica sobre la atención integral a las personas con enfermedad de Alzheimer y otras demencias. Guías de práctica clínica en el SNS Ministerio de Sanidad, Política Social e Igualdad. 2011.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. N Engl J Med. 2012 March;366:893-903.
Kales HC Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia .BMJ. 2015; 350:h319. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707529/?report=printable
Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Recommendations for family physicians. Canadian Family Physician • Le Médecin de famille canadien. 2014;60:433-7.
Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. Up To DATE 2018.
Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008191. doi: 10.1002/14651858.CD008191.pub2.
The IPA Complete Guides to Behavioral and Psychological Symptoms of Dementia. Disponible en: https://www.ipa-online.org/news-and-issues/ipa-complete-guides-to-behavioral-and-psychological-symptoms-of-dementia-bpsd--2015-revision-release

Distonía

Jinnah HA, Stewart A. Diagnosis and Treatment of Dystonia. Neurol Clin. 2015;33:77-100.
Kartha N. Therapeutic Challenges in Dystonia. Neurol Clin. 2010; 28:927-40.
Welter ML, Grabli D, Vidailhet M. Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Current Opinion in Neurology. 2010;23(4):420-5.

Epilepsia

Algoritmo de tratamiento farmacológico de la epilepsia . Disponible en: http://www.cadime.es/docs/algoritmos/CADIME_ALGORITMO_TTO_EPILEPSIA_2017.pdf
Liu G, Slater N, Perkios A Epilepsy: Treatment Options RSSAmerican Family Physician, 2017-07-15, 96, Número 2, Páginas 87-96,
Nevitt SJ1, Sudell M, Weston J, Tudur Smith C, Marson AG.Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 Jun 29;6:CD011412. doi: 10.1002/14651858.CD011412.pub2.
Agencia Española de Medicamentos y Productos Sanitarios. Ácido valproico: nuevas medidas para evitar la exposición durante el embarazo. Ministerio de Salud, Consumo y Bienestar Social; 13 de febrero de 2018. Disponible en: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2018/NI-MUH_FV_3-acido-valproico.htm
NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (partial update of NICE clinical guideline). NICE guideline. 2011 Jan. Disponible en: http://www.nice.org.uk/nicemedia/live/12108/52447/52447.pdf
NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE 2012. Disponible en: http://guidance.nice.org.uk/CG20
Schmidt D, Schachter S. Drug treatment of epilepsy in adults. BMJ. 2014;348:1-18.
Steven C, Schachter, MD Overview of the management of epilepsy in adults. Up ToDATE Aug 2018
Tudur Smitts C, Weston J, Marson A. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data reviewCochrane Database of Systematic Reviews. 2018

Neuralgia del trigémino

Bajwa Z, Ho CH C, Khan S.Trigeminal neuralgia. UpTo DATE Aug 2018.
Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchie K, et al. The diagnostic evaluation and treatment of trigeminal. Neurology 2008;71;1183-90. Disponible en: http://www.neurology.org/content/70/22/2067.full

Parálisis facial

De Almeida JR, Guyatt G, Sud S, Dorion J, Hill M, Kolber MR, et al. Management of Bell palsy: clinical practice guideline. CMAJ. 2014;186(12): 917-22.
Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F, et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2015 Jul 1;7:CD001869.
Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F, Sullivan F Antiviral treatment for Bell’s palsy (idiopathic facial paralysis) (Review) Cochrane Database of Systematic Review 015.
Madhok VB, Gagyor I, Daly F, Somasundara D, Sullivan M, Gammie F, Sullivan F. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev Publicado July 18, 2016.
Numthavaj P, ThakkinstianA, Dejthevaporn Ch, Attia J.Corticosteroid and antiviral therapy for Bell's palsy: A network meta-analysis. BMC Neurol. 2011;11:1. Disponible en: http://www.biomedcentral.com/1471-2377/11/
Ronthal B. Bell's palsy: Treatment and prognosis in adults. UpToDATE Aug 2018
Turgeon RD, Wilby KJ, Ensom MH. Antiviral Treatment of Bell’s Palsy Based on Baseline Severity: A Systematic Review and Meta-analysis. The American Journal of Medicine 2015; 6,128: 617-28.

Parkinson. Enfermedad

Algoritmo de tratamiento farmacológico de la enfermedad de Parkinson Disponible en: http://www.cadime.es/docs/algoritmos/CADIME_ALGORITMO_PARKINSON_2016_.pdf
Alonso Cánovas A, Luquin Piudo R, García Ruiz-Espiga P, Burguera JA, Campos Arillo V, Castro A, et al. Agonistas dopaminérgicos en la enfermedad de Parkinson. Neurología. 2014;29(4):230-41.
Connolly B, Lang AE. Pharmacological Treatment of Parkinson Disease A Review. JAMA. 2014;311(16):1670-83.
Diagnosis and pharmacological management of Parkinson's disease. A national clinical guideline 2010. Disponible en: www.sign.ac.uk/guidelines/fulltext/50/index.html
Enfermedad de Parkinson: aspectos prácticos. Disponible en: http://www.osanet.euskadi.net/cevime/es
Grupo Andaluz de Trastornos del Movimiento de la Sociedad Andaluza de Neurología. Enfermedad de Parkinson. Recomendaciones de Práctica Clínica. Sociedad Andaluza de Neurología. Sevilla. 2012. Disponible en: http://www.actasanitaria.com/fileset/file__Gu_a_Parkinson_56911.pdf
Mercade Cerda JM, Toledo Argani M, Mauri Llerda JA, Lopez Gonzalez FJ, Lopez Gonzalez X, Salas Puig J, Sancho Rieger J Guía oficial de la Sociedad Española de Neurología de práctica clínica en Epilepsia. Neurología Volume 31, Issue 2, March 2016, Pages 121-129.
Management of Parkinson Disease in 2017. Personalized Approaches for Patient-Specific Needs. JAMA 2017. V318, Nº 9 :791-792.
Ossig C, Reichmann H. Treatment Strategies in Early and Advanced Parkinson Disease. Neurol Clin. 2015;33:19-37.
Parkinson’s disease in adults NICE guideline Published: 19 July 2017 Disponible en: https://www.nice.org.uk/guidance/ng71
Stowe RL, Ives NJ, Clarke C, Deane K, van Hilten, Wheatley K, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´ s disease patients with motor complications. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD007166.
Tarsy D. Pharmacologic treatment of Parkinson disease. UpToDate. Aug. 2018.
Traitement de la maladie de Parkinson. Réduire les fluctuations motrices sous lévodopa. Prescrire. 2011;31:273-9.

Polineuritis

Ansari Z. Evidence-based pharmacological management of chronic neuropathic pain. Int J Basic Clin Pharmacol. 2013;2:229-36.
Attal N, Cruccu G, Baron R, Haanpa M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-23.
Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015; Issue 1. Art. No.: CD011209.
King JB, Schauerhamer MB, Bellows BK. A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain. Therapeutics and Clinical Risk Management. 2015;11:1163-75.
Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE clinical guideline. 2010. Disponible en: http://www.nice.org.uk/nicemedia/live/12948/47949/47949.pdf
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;(4):CD005454.
Westaway KP, Alderman P, Frank OR, Husband AJ, Rowett D, Blanc TL. Optimising Therapy for Patients with Neuropathic Christopher Journal of Pharmacy Practice and Research. 2014;1:44-7.

Temblor esencial

Bruno E, Nicoletti A, Quattrocchi G, Allegra R, Filippini G, Colosimo C, Zappia M.. Topiramate for essential tremor (review). Cochrane Database of Systematic Review 2017.
Fasano A, Deuschl G. Therapeutic Advances in Tremor. Movement Disorders. 2015;30;11:1957-65.
Günther G, Raethjen J, Hellriege Hl, Elble R. Treatment of patients with essential tremor. Lancet Neurol. 2011;10:148-61.
Labiano-Fontcuberta A, Benito-León J. Temblor esencial: una actualización. Med Clin (Barc). 2013;140(3):128-33.
Sadeghi R, Ondo WG. Pharmacological Management of Essential Tremor. Drugs. 2010;70(17):2215-28.
Tarsy D. Essential tremor: Treatment and prognosis. Up ToDATE Aug 2018.

Tics

Black KJ. Tourette Syndrome and Other Tic Disorders. Disponible en: http://www.emedicine.com/NEURO/topic664.htm
Chadehumbe MA, Greydanus DE, Feucht C, Patel DR. Psychopharmacology of Tic Disorders in Children and Adolescents. Pediatr Clin N Am. 2011;58:259-72.
Dure LS, DeWolfe J.Treatment of tics. Adv Neurol 2006;99:191-6.
Franklin SA, Walther MR, Woods DW. Behavioral Interventions for Tic Disorders. Psychiatr Clin N Am. 2010;33:641-55.
Pringsheim T, Davenport W, Lang A. Tics. Curr Opin Neurol 2003;16:523-7.
Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011 April;20(4):173-96. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065650/

Vértigo periférico

Bhattacharyya N, Baugh RF, Orvidas L, Barrs D, Bronston L, Cass S, et al. Clinical practice guideline: Benign paroxysmal positional vertigo. Otolaryngology-Head and Neck Surgery 2008;139,S47-S8. Disponible en: http://www.entnet.org/Practice/upload/BPPV-guideline-final-journal.pdf
Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngol Ital 2006 Aug;26(4):208-15.
Fife TD, Iverson DJ, Lempert T, et al. Therapies for benign paroxysmal positionaL vertigo (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2008;70;2067. Disponible en: http://www.neurology.org/content/70/22/2067.full.html
Murdin L, Hussain K, Schilder A. Betahistina para los síntomas del vértigo. Cochrane Database of Systematic Reviews 2016 Issue 6. Art. No.: CD010696. DOI: 10.1002/14651858.CD010696